Intrexon (NYSE:XON) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.21), Briefing.com reports. The business had revenue of $32.45 million for the quarter, compared to analysts’ expectations of $35.98 million. During the same quarter in the prior year, the company posted ($0.33) EPS. Intrexon’s revenue was down 29.5% on a year-over-year basis.
Shares of XON stock traded down $2.45 on Friday, hitting $10.77. The company’s stock had a trading volume of 2,685,397 shares, compared to its average volume of 1,557,050. Intrexon has a fifty-two week low of $10.26 and a fifty-two week high of $20.16.
Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Intrexon from a “buy” rating to a “hold” rating in a report on Monday, October 15th. JMP Securities upped their price objective on shares of Intrexon from $42.00 to $43.00 and gave the company a “market outperform” rating in a report on Wednesday, October 10th. ValuEngine upgraded shares of Intrexon from a “sell” rating to a “hold” rating in a report on Monday, September 24th. Stifel Nicolaus initiated coverage on shares of Intrexon in a report on Tuesday, July 17th. They issued a “buy” rating and a $72.00 price objective on the stock. Finally, Bank of America downgraded shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 price target on the stock. in a research note on Monday, July 16th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $29.67.
In related news, SVP Joel D. Liffman sold 79,000 shares of the company’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $14.59, for a total value of $1,152,610.00. Following the transaction, the senior vice president now directly owns 79,500 shares in the company, valued at $1,159,905. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 48.20% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in XON. SG Americas Securities LLC acquired a new position in shares of Intrexon in the third quarter valued at about $131,000. BB&T Securities LLC bought a new stake in Intrexon during the second quarter worth about $175,000. Chessman Wealth Strategies RIA bought a new stake in Intrexon during the second quarter worth about $205,000. John G Ullman & Associates Inc. bought a new stake in Intrexon during the third quarter worth about $258,000. Finally, Metropolitan Life Insurance Co. NY lifted its position in Intrexon by 477.9% during the second quarter. Metropolitan Life Insurance Co. NY now owns 23,140 shares of the biotechnology company’s stock worth $323,000 after purchasing an additional 19,136 shares during the period. Institutional investors and hedge funds own 84.92% of the company’s stock.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Recommended Story: Preferred Stock
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.